伊布替尼治疗淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的疗效与安全性
回顾性分析中国医学科学院血液病医院2016年3月至2023年6月接受伊布替尼治疗的98例初治及复发难治淋巴浆细胞淋巴瘤/华氏巨球蛋白血症患者,初治45例、复发难治53例。可评估疗效88例,主要缓解率78.4%、总缓解率85.2%,初治与复发难治患者间差异均无统计学意义。
要点
- 伊布替尼治疗初治及复发难治LPL/WM的MRR为78.4%、ORR为85.2%。
- 初治与复发难治患者MRR和ORR差异均无统计学意义。
- 主要不良反应为高尿酸血症21.4%、肺炎8.1%、血小板减少5.1%,心房颤动2.0%。
核心结论
- 伊布替尼对于初治及复发难治LPL/WM患者有良好的疗效及安全性。
研究设计与样本
- 回顾性收集2016年3月至2023年6月在中国医学科学院血液病医院接受伊布替尼治疗的98例初治及复发难治LPL/WM患者临床资料。
- 共纳入98例,初治45例、复发难治53例,男74例(75.5%),中位年龄64(42~87)岁。
主要发现
- 88例可评估疗效,中位治疗时间20.8(2.1~55.0)个月,主要缓解率78.4%、总缓解率85.2%。
- 初治患者MRR 78.4%、ORR 86.5%,复发难治患者MRR 78.4%、ORR 84.3%,差异均无统计学意义(P值均>0.05)。
- 中位随访29.1(2.9~50.3)个月,初治和复发难治患者中位总生存时间均未达到,中位无进展生存时间分别为23.5(95%CI 10.5~36.5)个月和45.0(95%CI 34.0~56.0)个月,差异均无统计学意义(P值均>0.05)。
- 死亡患者25例,未出现因应用伊布替尼死亡事件。
- 主要不良反应为血小板减少(5.1%)、肺炎(8.1%)及高尿酸血症(21.4%),心房颤动发生率为2.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the efficacy and safety of ibrutinib for the treatment of newly treated and relapsed refractory (R/R) lymphoplasmacytic lymphoma (LPL) /Waldenström macroglobulinemia (WM) . Methods: Retrospectively collected clinical data of 98 cases of newly treated and R/R LPL/WM patients who received ibrutinib treatment at the Hematology & Blood Diseases Hospital of the Chinese Academy of Medical Sciences from March 2016 to June 2023, and analyzed their efficacy and safety. Results: A total of 98 LPL/WM patients were included, which consisted of 45 newly treated patients and 53 R/R patients. Of these, 74 were males (75.5%) and the cohort had a median age of 64 (42-87) years. Eighty-eight patients were eligible for efficacy evaluation with a median treatment time of 20.8 (2.1-55.0) months, a major remission rate (MRR) of 78.4%, and an overall response rate (ORR) of 85.2%. The MRR and ORR of the newly treated patients were 78.4% and 86.5%, respectively, whereas the MRR and ORR of the R/R patients were 78.4% and 84.3%, respectively. There were no statistically significant differences in MRR and ORR between the initial treatment and R/R patients (all P values >0.05) . The median follow-up period was 29.1 (2.9-50.3) months and the median overall survival time for newly treated and R/R patients was not reached. The median progression-free survival time was 23.5 (95% CI 10.5-36.5) months and 45.0 (95% CI 34.0-56.0) months, respectively, with no statistically significant differences (all P values >0.05) . There were 25 deceased patients and no deaths were related to ibrutinib treatment. The main adverse reactions of ibrutinib were thrombocytopenia (5.1%) , pneumonia (8.1%) , and hyperuricemia (21.4%) . The incidence of atrial fibrillation was 2.0%. Conclusion: Ibrutinib exhibits good efficacy and safety for newly treated and R/R LPL/WM patients. 目的: 探索伊布替尼治疗初治及复发难治(R/R)淋巴浆细胞淋巴瘤(LPL)/华氏巨球蛋白血症(WM)的疗效及安全性。 方法: 收集2016年3月至2023年6月在中国医学科学院血液病医院接受伊布替尼治疗的98例初治及R/R LPL/WM患者的临床资料,回顾性分析其疗效及安全性。 结果: 共纳入98例LPL/WM患者,初治患者45例,R/R患者53例,男74例(75.5%),中位年龄64(42~87)岁。88例患者可进行疗效评估,中位治疗时间20.8(2.1~55.0)个月,主要缓解率(MRR)为78.4%,总缓解率(ORR)为85.2%。初治患者的MRR和ORR分别为78.4%和86.5%,R/R患者的MRR和ORR分别为78.4%和84.3%,初治与R/R患者MRR和ORR的差异均无统计学意义(P值均>0.05)。中位随访29.1(2.9~50.3)个月,初治和R/R患者的中位总生存时间均未达到,中位无进展生存时间分别为23.5(95%CI 10.5~36.5)个月和45.0(95%CI 34.0~56.0)个月,差异均无统计学意义(P值均>0.05)。死亡患者25例,未出现因应用伊布替尼死亡事件,伊布替尼的主要不良反应为血小板减少(5.1%)、肺炎(8.1%)及高尿酸血症(21.4%),心房颤动的发生率为2.0%。 结论: 伊布替尼对于初治及R/R LPL/WM患者有良好的疗效及安全性。.
引用
- Huang YS, Xiong WJ, Yuan JJ, et al. [The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39307722. doi:10.3760/cma.j.cn121090-20240301-00077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。